Development of Prediction Models for Carbapenem-resistant Acquisition and Prognosis in Adult Patients

Overview

Journal Front Pharmacol

Date 2024 Nov 20

PMID 39564105

Authors

Huijuan Yao

Yu Yang

Huimin Yao

Shuhong Bu

Lixia Li

Fang Wang

Jian Zhang

Jihui Chen

Affiliations

Soon will be listed here.

Abstract

Objectives: To explore the risk factors and clinical outcomes of carbapenem-resistant (CRKP) infection and establish nomograms to predict the probability of CRKP infection and mortality in adult patients.

Methods: Patients infected with KP from August 2019 to April 2021 in a tertiary hospital in Shanghai were enrolled. Risk factors associated with CRKP and 30-day mortality were identified using multivariate logistic regression analysis and Cox regression analysis.

Results: Overall, 467 patients with KP infection were enrolled, wherein 210 (45.0%) patients were infected with CRKP and 257 (55.0%) patients with carbapenem-susceptible (CSKP). Five factors, namely Charlson's Comorbidity Index (CCI) ≥ 3, the use of central venous catheterization, prior hospitalization during the 3 months before infection, and previous exposure to carbapenems and broad-spectrum β-lactams, were found to be independently associated with CRKP infection. Based on these parameters, the nomogram showed a better performance as indicated by C-index of 0.94 (95% confidence interval [CI]: 0.92-0.96) and well-fitted calibration curves. CRKP was independently associated with 30-day mortality. Multivariate Cox regression analysis revealed that age ≥65 years, higher CCI scores, higher Sequential Organ Failure Assessment scores, the presence of respiratory failure, albumin levels ≤30 g/L, and non-appropriate treatments in 3 days, were associated with 30-day mortality.

Conclusion: The predictive nomogram established in this study can facilitate the clinicians to make better clinical decisions when treating patients with KP infection.

References

Chen J, Yang Y, Yao H, Bu S, Li L, Wang F . Prediction of Prognosis in Adult Patients With Carbapenem-Resistant Infection. Front Cell Infect Microbiol. 2022; 11:818308. PMC: 8787092. DOI: 10.3389/fcimb.2021.818308. View

Kohler P, Volling C, Green K, Uleryk E, Shah P, McGeer A . Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis. Infect Control Hosp Epidemiol. 2017; 38(11):1319-1328. DOI: 10.1017/ice.2017.197. View

Xu M, Fu Y, Kong H, Chen X, Chen Y, Li L . Bloodstream infections caused by Klebsiella pneumoniae: prevalence of bla, virulence factors and their impacts on clinical outcome. BMC Infect Dis. 2018; 18(1):358. PMC: 6069789. DOI: 10.1186/s12879-018-3263-x. View

Xu L, Sun X, Ma X . Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017; 16(1):18. PMC: 5371217. DOI: 10.1186/s12941-017-0191-3. View

Steyerberg E, Vergouwe Y . Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014; 35(29):1925-31. PMC: 4155437. DOI: 10.1093/eurheartj/ehu207. View

Zuo Y, Zhao D, Song G, Li J, Xu Y, Wang Z . Risk Factors, Molecular Epidemiology, and Outcomes of Carbapenem-Resistant Infection for Hospital-Acquired Pneumonia: A Matched Case-Control Study in Eastern China During 2015-2017. Microb Drug Resist. 2020; 27(2):204-211. DOI: 10.1089/mdr.2020.0162. View

Agyeman A, Bergen P, Rao G, Nation R, Landersdorfer C . Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant infections (a meta-analysis dataset). Data Brief. 2019; 28:104907. PMC: 6921139. DOI: 10.1016/j.dib.2019.104907. View

Bengoechea J, Sa Pessoa J . Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2018; 43(2):123-144. PMC: 6435446. DOI: 10.1093/femsre/fuy043. View

Park S . Nomogram: An analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 2018; 155(4):1793. DOI: 10.1016/j.jtcvs.2017.12.107. View

10.

Forbes J, Knox N, Ronholm J, Pagotto F, Reimer A . Metagenomics: The Next Culture-Independent Game Changer. Front Microbiol. 2017; 8:1069. PMC: 5495826. DOI: 10.3389/fmicb.2017.01069. View

11.

Leguia M, Vila-Sanjurjo A, Chain P, Berry I, Jarman R, Pollett S . Precision Medicine and Precision Public Health in the Era of Pathogen Next-Generation Sequencing. J Infect Dis. 2019; 221(Suppl 3):S289-S291. PMC: 7101274. DOI: 10.1093/infdis/jiz424. View

12.

Yuan Y, Wang J, Yao Z, Ma B, Li Y, Yan W . Risk Factors for Carbapenem-Resistant Bloodstream Infections and Outcomes. Infect Drug Resist. 2020; 13:207-215. PMC: 6985980. DOI: 10.2147/IDR.S223243. View

13.

Liu P, Li X, Luo M, Xu X, Su K, Chen S . Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection: A Meta-Analysis. Microb Drug Resist. 2017; 24(2):190-198. PMC: 5873294. DOI: 10.1089/mdr.2017.0061. View

14.

Rodriguez-Medina N, Barrios-Camacho H, Duran-Bedolla J, Garza-Ramos U . : an emerging pathogen in humans. Emerg Microbes Infect. 2019; 8(1):973-988. PMC: 6609320. DOI: 10.1080/22221751.2019.1634981. View

15.

Del Puente F, Giacobbe D, Salsano A, Maraolo A, Ong D, Yusuf E . Epidemiology and outcome of carbapenemase-producing (KPC-KP) infections in cardiac surgery patients: a brief narrative review. J Chemother. 2019; 31(7-8):359-366. DOI: 10.1080/1120009X.2019.1685794. View

16.

Dai G, Xu Y, Kong H, Xie W, Wang H . Risk factors for carbapenem-resistant infection and associated clinical outcomes. Am J Transl Res. 2021; 13(6):7276-7281. PMC: 8290679. View

17.

Xiao T, Zhu Y, Zhang S, Wang Y, Shen P, Zhou Y . A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients. J Infect Dis. 2020; 221(Suppl 2):S174-S183. DOI: 10.1093/infdis/jiz559. View

18.

Li J, Li Y, Song N, Chen Y . Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: A meta-analysis. J Glob Antimicrob Resist. 2019; 21:306-313. DOI: 10.1016/j.jgar.2019.09.006. View

19.

Qureshi Z, Paterson D, Potoski B, Kilayko M, Sandovsky G, Sordillo E . Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012; 56(4):2108-13. PMC: 3318350. DOI: 10.1128/AAC.06268-11. View

20.

Liu H, Zhang Y, Yang J, Liu Y, Chen J . Application of mNGS in the Etiological Analysis of Lower Respiratory Tract Infections and the Prediction of Drug Resistance. Microbiol Spectr. 2022; 10(1):e0250221. PMC: 8849087. DOI: 10.1128/spectrum.02502-21. View